

Background
Bioprocessing evolves to meet the urgent need for efficient and cost-effective production methods capable of addressing the growing global demand for biopharmaceuticals. The core objective of bioprocess development is to facilitate large-scale manufacturing that can effectively address this increasing demand, especially in light of the rising prevalence of infectious diseases worldwide. Biological peptide synthesis is a pivotal component in this landscape, involving the biosynthesis of peptides within living cells that closely mimic natural processes. This method offers several significant advantages, including the ability to produce complex peptides with essential post-translational modifications, scalability suitable for industrial-scale production, and enhanced sustainability and cost efficiency. Consequently, biological peptide synthesis is widely adopted in pharmaceutical and biotechnology sectors for the manufacture of therapeutic peptides, research reagents, and vaccine constituents. It is particularly valuable for synthesizing peptides that are challenging to produce through chemical synthesis or that require specific biological modifications.






.png/_jcr_content/renditions/cq5dam.web.1280.1280.png)
.png/_jcr_content/renditions/cq5dam.web.1280.1280.png)


